Zhang Fan, Zhu Ping, Wu Li-Hui
Graduate School of Bengbu Medical College, Bengbu, Anhui 233000, China.
Zhongguo Dang Dai Er Ke Za Zhi. 2020 Feb;22(2):152-157. doi: 10.7499/j.issn.1008-8830.2020.02.013.
To study the association of microRNA expression before and after drug therapy with clinical symptoms in children with attention deficit hyperactivity disorder (ADHD).
A total of 80 previously untreated children with ADHD who were diagnosed from May 2017 to October 2018 were enrolled. The children who were willing to receive drug therapy were randomly divided into concerta-treated group with 31 children and strattera-treated group with 33 children. The children who were unwilling to receive treatment were enrolled as the untreated group with 16 children. A total of 60 children who underwent physical examination during the same period of time were enrolled as the healthy control group. SNAP-V score was determined at initial diagnosis and 3 and 6 months of follow-up. Serum samples were collected from the children with ADHD and the healthy control group. Quantitative real-time PCR was used to measure the relative expression of miR-4566-3p and miR-7641.
The repeated measures analysis of variance showed that the SNAP-V score of attention deficit symptoms were different among the two treatment groups and the untreated group at the first visit and 3 months and 6 months after treatment (P<0.05). There were significant differences in the relative expression of the two miRNAs among the two treatment groups and the healthy control group at the first visit and 3 months and 6 months after treatment (P<0.05). The SNAP-V score of attention deficit symptoms and the relative expression of the two miRNAs were different in different time points in the subjects (P<0.05). There were interactions between grouping and time factors in the SNAP-V score of attention deficit symptoms and the relative expression of the two miRNAs (P<0.05). The SNAP-V score of hyperactive impulsive symptoms was different in different time points in the two treatment groups and the untreated group (P<0.05), but the significant difference in the score was not observed between two treatment groups and the untreated group (P>0.05), and there was no interaction between the time factor and the grouping factor (P>0.05). The SNAP-V score of attention deficit symptoms was negatively correlated with the relative expression of miRNA-4655-3p and miRNA-7641 (r=-0.314, -0.495 respectively; P<0.05) in ADHD children after drug treatment.
Drug therapy can significantly improve the clinical symptoms of children with ADHD. The expression of miR-4655-3p and miR-7641 in serum can be used as biomarkers for the diagnosis and outcome evaluation of ADHD.
研究注意缺陷多动障碍（ADHD）患儿药物治疗前后微小RNA表达与临床症状的相关性。
纳入2017年5月至2018年10月期间诊断的80例未经治疗的ADHD患儿。愿意接受药物治疗的患儿被随机分为31例的康纳达治疗组和33例的择思达治疗组。不愿接受治疗的患儿作为16例的未治疗组。同期接受体检的60例儿童作为健康对照组。在初诊及随访3个月和6个月时测定SNAP-V评分。采集ADHD患儿和健康对照组儿童的血清样本。采用定量实时PCR检测miR-4566-3p和miR-7641的相对表达。
重复测量方差分析显示，两个治疗组和未治疗组在首次就诊时以及治疗后3个月和6个月时，注意缺陷症状的SNAP-V评分存在差异（P<0.05）。两个治疗组与健康对照组在首次就诊时以及治疗后3个月和6个月时，两种微小RNA的相对表达存在显著差异（P<0.05）。受试者不同时间点的注意缺陷症状SNAP-V评分和两种微小RNA的相对表达存在差异（P<0.05）。注意缺陷症状的SNAP-V评分和两种微小RNA的相对表达在分组和时间因素之间存在交互作用（P<0.05）。两个治疗组和未治疗组不同时间点的多动冲动症状SNAP-V评分存在差异（P<0.05），但两个治疗组与未治疗组之间评分无显著差异（P>0.05），时间因素与分组因素之间无交互作用（P>0.05）。药物治疗后ADHD患儿注意缺陷症状的SNAP-V评分与miRNA-4655-3p和miRNA-7641的相对表达呈负相关（r分别为-0.314、-0.495；P<0.05）。
药物治疗可显著改善ADHD患儿的临床症状。血清中miR-4655-3p和miR-7641的表达可作为ADHD诊断和疗效评估的生物标志物。
